Skip to content

Hair Benefit Study For The Test Products

To evaluate the Safety & Anti-dandruff efficacy of test products & test regimen in comparison to placebo & control on healthy human volunteers suffering from dandruff.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/02/049737
Enrollment
415
Registered
2023-02-15
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L219- Seborrheic dermatitis, unspecified

Interventions

None listed

Sponsors

Unilever Industries Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female and male participants in the ratio of 2:1 in general good health. 2. Participants in the age group 18-45 years (both the ages inclusive). 3. Participants willing to give a written informed consent and agree to come for a regular follow up visit. 4. Participants with mild dandruff score of = 40 (adherent (ASFS) + non-adherent dandruff (non-ASFS)) 5. Participants willing to abide by and comply with the study protocol. 6. Participants who have not participated in a similar investigation in the past three months. 7. Participants who agree to refrain from using hair dye / hair colour /henna during the study period. 8. Participants willing to refrain from any type of hair treatment like perming, straightening etc. during the study duration 9. Participants willing to refrain from any other anti-dandruff treatment/ products (including lotions/ home remedies/ oils/ serum/ mask) during the course of the study 10. Participants who agree to use test product & regimen (including hair oils).

Exclusion criteria

Exclusion criteria: 1. Participants who have undergone hair growth treatment within 3 months before screening into the study. 2. Participants having any active scalp disease which may interfere in the study – dermatologist’s judgement. 3. Participants with medicated / antidandruff oil will be excluded 4. Participants (male) having androgenic alopecia, male pattern baldness’ not be included in study. 5. Participants who have taken chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study. 6. Participants (females) who are pregnant or lactating 7. Participants who have had hair transplant. 8. A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products. 9. Chronic illness which may influence the cutaneous state. 10. Participants participating in other similar cosmetic or therapeutic trial within last three months 11. Any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness. 12. Participants (males) who are having androgenic alopecia, male pattern baldness

Design outcomes

Primary

MeasureTime frame
Significant improvement in dandruff condition by expert/dermatologist assessmentTimepoint: 4 weeks product and 2 weeks regression

Secondary

MeasureTime frame
Significant reduction and prevention of dandruff associated conditions by expert/dermatologist assessmentTimepoint: 4 weeks product and 2 weeks regression

Countries

India

Contacts

Public ContactSudhanthiran S

MS Clinical Research Pvt Ltd

arya.p@msclinical.com08041125934

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026